EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Post-marketing safety of givinostat in Duchenne muscular dystrophy: analysis of the FDA Adverse Event Reporting System

Azad Mammadov, Damla Binnetoğlu

Ars Pharmaceutica (Internet) · 20.06.2026 · 67 (3) · 328-337

DOI: 10.30827/ars.v67i3.36214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ars Pharmaceutica (Internet), online erschienen am 20.06.2026. Verfasst von Azad Mammadov und 1 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate adverse events reported with givinostat using spontaneous reports from the FDA Adverse Event Reporting System (FAERS) following its March 2024 approval for Duchenne muscular dystrophy.

Methods

Reports from Q2 2024 through Q3 2025 were retrieved, keeping only cases listing givinostat as primary suspect. Disproportionality was assessed via reporting odds ratio, proportional reporting ratio, Bayesian Confidence Propagation Neural Network, and Multi-item Gamma Poisson Shrinker; positive signals required agreement across all methods. A sensitivity analysis excluding reports with concomitant corticosteroids was conducted.

Results

After removing duplicates, 254 reports with 586 events were analyzed. The cohort was predominantly male (97.6 %) with median age 14 years. Petechiae generated the highest reporting odds ratio (45.21; n=4), though thrombocytopenia was more frequent (ROR 18.85; n=24). Gastrointestinal complaints predominated numerically. Onset clustering was evident, with 68.3 % of the quantifiable subset occurring within 30 days; Weibull analysis confirmed early-failure hazard (β=0.47). Sensitivity analysis excluding corticosteroid-users confirmed the robustness of key signals.

Conclusions

Post-marketing findings largely mirror clinical trial observations. Visibility of cutaneous manifestations like petechiae probably enhances their reporting. Close surveillance during initial treatment weeks is recommended.

Zitieren

APA

Mammadov, A., & Binnetoğlu, D. (2026). Post-marketing safety of givinostat in Duchenne muscular dystrophy: analysis of the FDA Adverse Event Reporting System. Ars Pharmaceutica (Internet), 67(3), 328-337. https://doi.org/10.30827/ars.v67i3.36214

Vancouver

Mammadov A, Binnetoğlu D. Post-marketing safety of givinostat in Duchenne muscular dystrophy: analysis of the FDA Adverse Event Reporting System. Ars Pharmaceutica (Internet). 2026;67(3):328-337. doi:10.30827/ars.v67i3.36214

BibTeX
@article{Mammadov2026,
  author = {Mammadov, Azad and Binnetoğlu, Damla},
  title = {Post-marketing safety of givinostat in Duchenne muscular dystrophy: analysis of the FDA Adverse Event Reporting System},
  journal = {Ars Pharmaceutica (Internet)},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {328--337},
  doi = {10.30827/ars.v67i3.36214}
}
Kostenlos starten →